Literature DB >> 2386735

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.

N Rajaram1, R J Tatake, S H Advani, S G Gangal.   

Abstract

We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors--2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.

Entities:  

Mesh:

Year:  1990        PMID: 2386735      PMCID: PMC1971824          DOI: 10.1038/bjc.1990.261

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Production of interleukin-2 and expression of tac antigen in Hodgkin disease.

Authors:  N N Joshi; R Mukhopadhyay; S H Advani; S G Gangal
Journal:  Cancer Detect Prev Suppl       Date:  1987

Review 2.  Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.

Authors:  E A Grimm
Journal:  Biochim Biophys Acta       Date:  1986-12-17

Review 3.  Hodgkin disease: malignancy, inflammation and abnormal immunity.

Authors:  E Aghai
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

4.  A killing defect of natural killer cells with the absence of natural killer cytotoxic factors in a child with Hodgkin's disease.

Authors:  A Komiyama; H Kawai; S Yamada; M Kato; M Yanagisawa; Y Miyagawa; T Akabane
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

5.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  Effect of exogenous interleukins on in vitro responses of T lymphocytes from patients with Hodgkin disease.

Authors:  R Mukhopadhyaya; S H Advani; S G Gangal
Journal:  Cancer Detect Prev       Date:  1987

7.  Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.

Authors:  K Oshimi; Y Oshimi; M Akutsu; Y Takei; H Saito; M Okada; H Mizoguchi
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

8.  Evaluation of carcinoembryonic antigen levels in gastric juice, stomach mucosa and plasma in high-risk and gastric cancer patients.

Authors:  M Castelli; S Guadagni; A Bagnato; M A Pistoia; M Carboni; E Sega
Journal:  Oncology       Date:  1986       Impact factor: 2.935

9.  Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission.

Authors:  M Dabholkar; S Advani; R Tatake; S Gangal
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

10.  Functional evaluation of T-lymphocytes from peripheral blood and spleens in Hodgkin's disease.

Authors:  R Mukhopadhyaya; S H Advani; S G Gangal
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more
  5 in total

1.  Clinical significance of natural killing activity in patients with advanced lymphoma.

Authors:  K Ono
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

2.  Natural killing activity in patients with spontaneous regression of malignant lymphoma.

Authors:  K Ono; M Kikuchi; N Funai; M Matsuzaki; Y Shimamoto
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

3.  Axl signaling induces development of natural killer cells in vitro and in vivo.

Authors:  Eun-Mi Kim; Eun-Hee Lee; Hwa-Yeon Lee; Ha-Rim Choi; Kon-Young Ji; Su-Man Kim; Kwang Dong Kim; Hyung-Sik Kang
Journal:  Protoplasma       Date:  2016-08-22       Impact factor: 3.356

4.  TREM2 promotes natural killer cell development in CD3-CD122+NK1.1+ pNK cells.

Authors:  Hwa-Youn Lee; Eun-Hee Lee; Jawoon Yi; Kon-Young Ji; Su-Man Kim; Ha-Rim Choi; Su-Min Yee; Hyung-Sik Kang; Eun-Mi Kim
Journal:  BMC Immunol       Date:  2021-05-12       Impact factor: 3.615

Review 5.  Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Authors:  Jodi Chiu; Daniel M Ernst; Armand Keating
Journal:  Front Immunol       Date:  2018-02-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.